RSS Newsfeeds

See all RSS Newsfeeds

Global Regions

United States ( XML Feed )

Aug 5, 2016 10:35 AM ET

Archived: AblaCor Medical Corporation’s mission is to develop a catheter ablation system that will significantly advance the treatment of atrial fibrillation (AF), the most common irregular heart rhythm

iCrowdNewswire - Aug 5, 2016

Ablacor 20standard 20logo 20160309

AblaCor Medical Corporation

AblaCor is developing a new medical product to significantly reduce the burden of atrial fibrillation, while providing a positive ROI for investors.

Cb 20in 20situ 20no 20labels

Company Summary


AblaCor’s mission is to develop a catheter ablation system that will significantly advance the treatment of atrial fibrillation (AF), the most common irregular heart rhythm. AblaCor’s CircumBlator™ system will enable a procedure that offers a low complication rate, shorter procedure times, and fewer repeat procedures. AblaCor’s competitive advantage is controlled contact with the heart tissue to provide consistent, continuous ablations.



  • StageProduct In Development
  • IndustryMedical Devices and Equipment
  • LocationNeedham, MA, USA
  • CurrencyUSD
  • FoundedJanuary 2013
  • Employees7
  • Websiteablacor.com



  • Mjs 20photo

    Martin is an entrepreneur, leader, and engineer with >25 years’ experience in business development and project management of successful medical products with revenues >$1B. He successfully led development of image-guided surgery, automated clinical analyzers, orthopedics, pain management, and drug delivery products. Martin was a founder and first president of the Medical Development Group, an industry organization for med-tech professionals.


  • 6bbffbd1 dbe6 4157 844b f7295c66a298
    Director, Strategic Management

    Joyce demonstrates leadership in strategic planning, clinical marketing, product management, and commercialization. She has a passion for innovation and the value it brings to patients, clinicians and the healthcare system. She was a product/program manager for Fresenius Medical Care where she led the launch of several treatments and diagnostic testing for renal patients including the drug, Epogen®.


  • 130518

    Roy has served in leadership roles for start-up, mid-range, and global companies. His expertise is in bringing new medical technologies out of the laboratory and into clinical use with demonstrated commercial success. In addition to successful launches in the United States, Roy has successfully launched several new products in Europe and Japan; supported, built, and maintained distribution channels; and established a local market presence.


  • 73c83c30 c4a3 4868 9ae5 9741f4df62df
    Director, Regulatory and Clinical

    Claire has over 30 years’ experience in clinical affairs with 20 years of management experience in the global, high-technology, medical device industry. She is a recognized expert in the areas of clinical research, key opinion leader programs, and physician training programs. She has a strong clinical knowledge base and a wide network of relationships with key opinion leaders in global cardiac rhythm management and electrophysiology.


  • Default avatar
    Bob Rioux
    Technology Development

    Bob is a senior R&D Executive with 20+ years of broad leadership and P&L experience in medical device industry with proven strengths in innovation (79 issued patents, more than 100 published, and more than 21 additionally filed), project leadership, R&D management, and sustaining engineering. He has successfully and consistently delivered innovative engineering programs on time and under budget.


  • Default avatar
    Jim Bricker

    Jim has served as President & CEO of six high tech companies, two of which he founded, and as a business consultant, aiding start-ups in the business planning and fundraising stages. He has successfully engaged individual investors, Angel groups, and Venture Capital groups in his companies. He holds two Bachelor’s degrees from M.I.T.: a B.S. in Mechanical Engineering and a B.S. in Management; as well as an MBA from the Harvard Business School.

Contact Information:

Martin Sklar

View Related News >